The lack of knowledge about the voluntary reporting system of adverse drug reactions as a major cause of underreporting: direct survey among health professionals

被引:42
作者
Garcia, Mariley Perez [2 ]
Figueras, Albert [1 ]
机构
[1] Univ Autonoma Barcelona, Hosp Vall dHebron, Fundacio Inst Catala Farmacol, Dept Farmacol & Terapeut, E-08035 Barcelona, Spain
[2] Knop Labs, Santiago, Chile
关键词
pharmacovigilance; underreporting; voluntary reporting; Venezuela; Latin America; CARE PROFESSIONALS; ATTITUDES; PHARMACISTS;
D O I
10.1002/pds.2193
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Underreporting suspected adverse drug reactions (ADRs) is one of the main problems that face the pharmacovigilance (PhV) systems based on yellow card schemes. Objectives To measure the knowledge level on the suspected ADR voluntary reporting system among physicians and pharmacists in Venezuela and to study its relationship with different variables. Methods A population-based, anonymous, and self-administered questionnaire was addressed to health professionals along the national territory of Venezuela. An algorithm was developed to classify the knowledge level on the voluntary reporting system. Results Taken as a whole, the level of knowledge on the voluntary reporting system was "poor." Among the 515 participant physicians, 62.3% (95%CI = 58.0-66.5%) had a "poor" level of knowledge; PhV was associated with "control" of medicines use, and only 24.7% had ever reported a suspected ADR. "Medical specialty" was the only variable that showed a relationship with the knowledge level (p = 0.0041). Among the 78 participant pharmacists, 66.7% had a "poor" knowledge level (95%CI = 55.1-76.9%). Conclusions The knowledge level on the voluntary reporting system among physicians and pharmacists in Venezuela is poor. These results strengthen the hypothesis that being unaware of the adverse effects of medicines and not knowing the existence of a PhV system is a major cause of underreporting. A careful study of the actual knowledge of PhV could be the basis to set up interventions specifically designed to overcome misleading concepts and to improve the reporting rate at a national level. Copyright (C) 2011 John Wiley & Sons, Ltd.
引用
收藏
页码:1295 / 1302
页数:8
相关论文
共 16 条
[1]  
Aagaard Lise, 2009, BMC Clin Pharmacol, V9, P4, DOI 10.1186/1472-6904-9-4
[2]   Reporting of adverse drug reactions: predictors of under-reporting in Malaysia [J].
Aziz, Zoriah ;
Siang, Tan Ching ;
Badarudin, Nurul Suhaida .
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2007, 16 (02) :223-228
[3]   Knowledge and attitudes of physicians relating to reporting of adverse drug reactions in Sokoto, north-western Nigeria [J].
Bello, Shaibu Oricha ;
Umar, Muhammad Tukur .
ANNALS OF AFRICAN MEDICINE, 2011, 10 (01) :13-18
[4]   ATTITUDINAL SURVEY OF ADVERSE DRUG REACTION REPORTING BY MEDICAL PRACTITIONERS IN THE UNITED-KINGDOM [J].
BELTON, KJ ;
LEWIS, SC ;
PAYNE, S ;
RAWLINS, MD ;
WOOD, SM .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1995, 39 (03) :223-226
[5]   Attitude survey of adverse drug-reaction reporting by health care professionals across the European Union [J].
Belton, KJ ;
Gram, LF ;
Royer, RJ ;
Feely, J ;
McGettigan, P ;
Velo, GP ;
Conforti, A ;
Leone, R ;
Stricker, BHC ;
Teixeira, F ;
Laporte, JP ;
Capella, D ;
Beermann, B ;
Lewis, SC ;
Payne, S ;
Rawlins, MD ;
Wood, SM .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 52 (06) :423-427
[6]  
De Vries TPGM., 1994, GUIDE GOOD PRESCRIBI
[7]   Spontaneous reporting of adverse drug reactions in Cuba:: integrating continuous education, training and research in a network approach [J].
Debesa, F ;
Jiménez, G ;
Figueras, A ;
Diogène, E ;
Peña, JP ;
Avila, J ;
Laporte, JR .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2002, 54 (03) :335-336
[8]   Physicians' knowledge and attitudes regarding the spontaneous reporting system for adverse drug reactions [J].
Hasford, J ;
Goettler, A ;
Munter, KH ;
Müller-Oerlinghausen, B .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 2002, 55 (09) :945-950
[9]  
HAZELL L, 2006, REV ART DRUG SAF, V29, P5
[10]  
HERDEIRO M, 2005, DRUG SAFETY, V28, P9